B of A Securities Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has initiated coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and set a price target of $29.

December 04, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma receives a Buy rating from B of A Securities with a price target of $29, indicating a positive outlook from the analyst.
The initiation of coverage by B of A Securities with a Buy rating typically suggests a positive outlook on the stock's future performance. The price target of $29 implies a level of expected upside from the current trading price. This can lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100